Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Kinder Morgan Inc (KMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Kinder Morgan Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while Kinder Morgan Inc trades at $33.37 (market cap $74.44B). The key difference: Kinder Morgan Inc is far larger — about 26× Dyne Therapeutics Inc. Common Stock's market cap, and Kinder Morgan Inc pays a 3.53% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Kinder Morgan Inc for 151 Days on average.
| DYN | KMI | |
|---|---|---|
Market Cap | $2.86B | $74.44B |
Volume | 3,341,579 | 10,771,998 |
Sector | Health | Energy |
52-Week High | $26.78 | $34.31 |
52-Week Low | $14.60 | $25.84 |
Typical Hold Time | 0 Days | 151 Days |
Enterprise Value | $2.18B | $106.49B |
Dividend Yield | — | 3.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Kinder Morgan (KMI) trades at $33.43, up 1.06% with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The company maintains solid fundamentals with $16.94B revenue, 19.31% net margin, and a $6B-$7B growth pipeline. Analyst consensus is mixed with 47% buy ratings and a $37.20 price target, while technical indicators show support at $33 and resistance at $34.
KMI offers income investors a compelling dividend yield with growth potential from natural gas infrastructure demand, though elevated debt levels and energy market volatility present risks. The stock's current valuation at 21.57 P/E appears reasonable given earnings growth trajectory and stable fee-based revenue model.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →
